Biohaven Pharma (BHVN) Tops Q4 EPS by 28c

Biohaven Pharma (NYSE: BHVN) reported Q4 EPS of ($2.69), $0.28 better than the analyst estimate of ($2.97). Revenue for the quarter came in at $35.1 million versus the consensus estimate of $28.23 million.

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Syensqo SA (SYENS:BB) PT Raised to EUR74 at Deutsche Bank
• AbbVie agrees to acquire Apogee Therapeutics for $10.9 billion